187 related articles for article (PubMed ID: 32576961)
1. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
Kloos A; Mintzas K; Winckler L; Gabdoulline R; Alwie Y; Jyotsana N; Kattre N; Schottmann R; Scherr M; Gupta C; Adams FF; Schwarzer A; Heckl D; Schambach A; Imren S; Humphries RK; Ganser A; Thol F; Heuser M
Leukemia; 2020 Nov; 34(11):2951-2963. PubMed ID: 32576961
[TBL] [Abstract][Full Text] [Related]
2. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
3. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma.
Hanft KM; Hamed E; Kaiser M; Würtemberger J; Schneider M; Pietsch T; Feige U; Meiss F; Krengel S; Niemeyer C; Hettmer S
Pediatr Blood Cancer; 2022 Apr; 69(4):e29468. PubMed ID: 34866327
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of chronic myelomonocytic leukemia.
Ramos Perez J; Montalban-Bravo G
Expert Opin Emerg Drugs; 2020 Dec; 25(4):515-529. PubMed ID: 33280448
[No Abstract] [Full Text] [Related]
6. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Machherndl-Spandl S; Stauder R; Zebisch A; Sill H; Öhler L; Kusec R; Hörmann G; Valent P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842710
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
8. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
[TBL] [Abstract][Full Text] [Related]
9. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
10. Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.
Taoka K; Arai S; Kataoka K; Hosoi M; Miyauchi M; Yamazaki S; Honda A; Aixinjueluo W; Kobayashi T; Kumano K; Yoshimi A; Otsu M; Niwa A; Nakahata T; Nakauchi H; Kurokawa M
Sci Rep; 2018 Oct; 8(1):15855. PubMed ID: 30367142
[TBL] [Abstract][Full Text] [Related]
11. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
12. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
14. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
15. Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.
Thomay K; Behrens YL; Lentes J; Wittner N; Wittig V; Rothe D; Steinemann D; Schlegelberger B; Göhring G
Leuk Lymphoma; 2018 Oct; 59(10):2478-2481. PubMed ID: 29384408
[No Abstract] [Full Text] [Related]
16. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.
Wang J; Liu Y; Li Z; Du J; Ryu MJ; Taylor PR; Fleming MD; Young KH; Pitot H; Zhang J
Blood; 2010 Dec; 116(26):5991-6002. PubMed ID: 20921338
[TBL] [Abstract][Full Text] [Related]
17. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
[TBL] [Abstract][Full Text] [Related]
18. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
Carr RM; Vorobyev D; Lasho T; Marks DL; Tolosa EJ; Vedder A; Almada LL; Yurcheko A; Padioleau I; Alver B; Coltro G; Binder M; Safgren SL; Horn I; You X; Solary E; Balasis ME; Berger K; Hiebert J; Witzig T; Buradkar A; Graf T; Valent P; Mangaonkar AA; Robertson KD; Howard MT; Kaufmann SH; Pin C; Fernandez-Zapico ME; Geissler K; Droin N; Padron E; Zhang J; Nikolaev S; Patnaik MM
Nat Commun; 2021 May; 12(1):2901. PubMed ID: 34006870
[TBL] [Abstract][Full Text] [Related]
19. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
